Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cancer research communications - 2(2022), 11 vom: 17. Nov., Seite 1449-1461 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McKenzie, Duncan R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/2767-9764.CRC-22-0298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353304530 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353304530 | ||
| 003 | DE-627 | ||
| 005 | 20240210232506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2767-9764.CRC-22-0298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM353304530 | ||
| 035 | |a (NLM)36824220 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McKenzie, Duncan R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse. Thus, whereas most patients with myelodysplastic syndrome were conspicuously good responders, some patients with other hematologic malignancies receiving cancer therapies within 2 weeks of vaccination showed no seroconversion despite three vaccine doses. Moreover, SARS-CoV-2 exposure during the course of the study neither prevented immunity waning, even in healthy controls, nor guaranteed vaccine responsiveness. These data offer real-world human immunologic insights that can inform health policy for patients with cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Graham, Rosalind |e verfasserin |4 aut | |
| 700 | 1 | |a Lechmere, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo-Vila, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Alaguthurai, Thanussuyah |e verfasserin |4 aut | |
| 700 | 1 | |a Arman, Celeste |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Gousis, Charalampos |e verfasserin |4 aut | |
| 700 | 1 | |a Kakkassery, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Carpenter, Esme |e verfasserin |4 aut | |
| 700 | 1 | |a Kurshan, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Vidler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Kulasekararaj, Austin |e verfasserin |4 aut | |
| 700 | 1 | |a Patten, Piers |e verfasserin |4 aut | |
| 700 | 1 | |a North, Bernard V |e verfasserin |4 aut | |
| 700 | 1 | |a Tree, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 700 | 1 | |a Hayday, Adrian C |e verfasserin |4 aut | |
| 700 | 1 | |a Irshad, Sheeba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research communications |d 2021 |g 2(2022), 11 vom: 17. Nov., Seite 1449-1461 |w (DE-627)NLM334868343 |x 2767-9764 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2022 |g number:11 |g day:17 |g month:11 |g pages:1449-1461 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2767-9764.CRC-22-0298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2022 |e 11 |b 17 |c 11 |h 1449-1461 | ||